Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Change in Acquisitions & Divestments (2019 - 2026)

DiaMedica Therapeutics filings provide 8 years of Change in Acquisitions & Divestments readings, the most recent being $16.8 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments rose 24.37% to $16.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.4 million through Mar 2026, up 3.28% year-over-year, with the annual reading at $57.1 million for FY2025, 3.18% down from the prior year.
  • Change in Acquisitions & Divestments hit $16.8 million in Q1 2026 for DiaMedica Therapeutics, up from $16.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $18.5 million in Q2 2025 and bottomed at $9.1 million in Q3 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $14.2 million, with a median of $14.5 million recorded in 2022.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 45.45% in 2024 before it crashed 43.1% in 2025.
  • DiaMedica Therapeutics' Change in Acquisitions & Divestments stood at $14.5 million in 2022, then dropped by 24.37% to $11.0 million in 2023, then surged by 45.45% to $16.0 million in 2024, then rose by 0.34% to $16.1 million in 2025, then rose by 4.58% to $16.8 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Change in Acquisitions & Divestments are $16.8 million (Q1 2026), $16.1 million (Q4 2025), and $9.1 million (Q3 2025).